Pimecrolimus cream 1%: A new development in nonsteroid topical treatment of inflammatory skin diseases

Seminars in Cutaneous Medicine and Surgery

Volumn 20, Issue 4, 2001, Pages 260-267

  Hebert, A A ^a   Warken, K A ^a   Cherill, R ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PIMECROLIMUS;

ARTICLE; ATOPIC DERMATITIS; BURN; CLINICAL TRIAL; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; HUMAN; LYMPHOCYTE ACTIVATION; PEDIATRICS; PSORIASIS; SKIN ALLERGY; SKIN INFLAMMATION; SKIN IRRITATION;

EID: 0035211542     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1053/sder.2001.29062     Document Type: Article

References (32)

1. Mechanisms of disease: Inflammatory skin diseases, T cells, and immune surveillance
2. Ascomycins: Promising agents for the treatment of inflammatory skin diseases
3. The prevalence of atopic dermatitis in Oregon schoolchildren
4. Natural history and clinical manifestations of atopic dermatitis
5. Biochemical and immunologic mechanisms in atopic dermatitis: New targets for emerging therapies
6. Atopic dermatitis: New insights and opportunities for therapeutic intervention
7. Occupational contact dermatitis in nurses with hand eczema
8. Incidence of work-related hand eczema during apprenticeship: First results of a prospective cohort study in the car industry
9. Prevalence of hand dermatitis in different occupations
10. Risk for hand eczema in employees with past or present atopic dermatitis
11. Hand eczema: An evaluation of the frequency of atopic background and the difference in clinical pattern between patients with and without atopic dermatitis
12. Hand eczema in metalworker trainees - An analysis of risk factors
13. Management of hand dermatitis
14. Long-term, intermittent treatment of chronic hand eczema with mometasone furoate
15. Hand dermatitis: Practical management and current concepts
16. Alterations in water content of the stratum corneum following long-term topical corticosteroids
17. Efficacy of a skin-protective foam in the treatment of chronic hand dermatitis
18. Disease management of atopic dermatitis: A practice parameter
19. New concepts in atopic dermatitis
20. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: In vivo pharmacology
21. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion
22. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis
23. Low blood concentrations of SDZ ASM 981 in infants with extensive atopic dermatitis treated with cream 1%
24. The eczema area and severity index (EASI): Assessment of reliability in atopic dermatitis
25. Oral SDZ ASM 981: Pharmacokinetic profile in humans
26. Oral SDZ ASM 981: Clinical safety, tolerability, and efficacy in patients with moderate to severe chronic plaque psoriasis
27. Safety and efficacy of ASM 981 (pimecrolimus) cream 1% in the treatment of atopic dermatitis in children and adolescents
28. The natural history of atopic dermatitis
29. Pimecrolimus (Elidel®, SDZ ASM 981) cream 1% is effective and safe in infants aged 3-23 months with atopic dermatitis
30. Long-term management with SDZ ASM 981 cream 1% of atopic dermatitis in pediatric patients
31. 1% SDZ ASM 981 cream effective in the treatment of chronic irritant hand dermatitis: A 6-week, randomized, double-blind, vehicle-controlled, single-center study
32. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: A randomized, double-blind controlled study